Skip to search formSkip to main contentSkip to account menu

dendritic cell-autologous lung tumor vaccine

Known as: DCVax-Lung 
A cancer vaccine consisting of lymphocytes harvested from a patient with lung cancer and induced to become antigen-presenting cells (APCs) known as… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
BackgroundStandard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the… 
Review
2015
Review
2015
Abstract 2491: Treatment with tumor lysate-pulsed autologous dendritic cells prolongs survival in patients with recurrent glioblastoma multiforme
Background The survival rate in recurrent Glioblastoma multiforme (rGBM) patients has not meaningfully changed in the past… 
Review
2015
Review
2015
ITOC2 – 017. Prolonged survival for patients with recurrent glioblastoma multiforme who are treated with tumour lysate-pulsed autologous dendritic cells
2013
2013
DCVax®- DIRECT: autologous activated dendritic cells for image guided intra-tumoral vaccination in patients with solid tumors - a phase I/II clinical trial in progress
Dendritic cells (DC) are acknowledged to be quintessential in the armamentarium to mount anti-tumor immune responses and have… 
Review
2009
Review
2009
DCVax®-Brain and DC vaccines in the treatment of GBM
Background: DCVax®-Brain (Northwest Biotherapeutics, Inc., Bethesda, MD, USA) is a personalized treatment for brain tumors. Its… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License